Multidrug resistance (MDR): A widespread phenomenon in pharmacological therapies

A Catalano, D Iacopetta, J Ceramella, D Scumaci… - Molecules, 2022 - mdpi.com
Multidrug resistance is a leading concern in public health. It describes a complex phenotype
whose predominant feature is resistance to a wide range of structurally unrelated cytotoxic …

Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs

MGG Sturkenboom, AG Märtson, EM Svensson… - Clinical …, 2021 - Springer
Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

AG Märtson, G Burch, S Ghimire… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Therapeutic drug monitoring (TDM) has been recommended for treatment
optimization in tuberculosis (TB) but is only is used in certain countries eg USA, Germany …

Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence

A Trébucq, T Decroo, A Van Deun, A Piubello… - Journal of clinical …, 2019 - mdpi.com
About ten years ago, the first results of the so-called “Bangladesh regimen”, a short regimen
lasting nine months instead of 20 months, revolutionized multidrug-resistant tuberculosis …

Treatment approaches to Mycobacterium abscessus pulmonary disease

MR Holt, T Baird - Clinics in Chest Medicine, 2023 - chestmed.theclinics.com
Mycobacterium abscessus complex is the most common cause of rapid-grower
nontuberculous mycobacterial pulmonary disease (NTM-PD) and a significant contributor to …

Therapeutic drug monitoring in non-tuberculosis mycobacteria infections

JW Alffenaar, AG Märtson, SK Heysell, JG Cho… - Clinical …, 2021 - Springer
Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to
progressive and life-threatening disease of multiple organs. Several factors such as …

Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease

A Sawka, A Burke - Clinics in Chest Medicine, 2023 - chestmed.theclinics.com
Treatment of nontuberculous mycobacteria (NTM) is lengthy and requires multiple antibiotics
some of which have specific toxicity concerns such as optic neuritis with ethambutol and …

Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis

JP Ernest, J Sarathy, N Wang, F Kaya… - Antimicrobial agents …, 2021 - Am Soc Microbiol
Amikacin and kanamycin are second-line injectables used in the treatment of multidrug-
resistant tuberculosis (MDR-TB) based on the clinical utility of streptomycin, another …

Low-dose amikacin in the treatment of multidrug-resistant tuberculosis (MDR-TB)

NF Sabur, MS Brar, L Wu, SK Brode - BMC Infectious Diseases, 2021 - Springer
Abstract Background The World Health Organization recommends intravenous amikacin for
the treatment of MDR-TB at a dose of 15 mg/kg. However, higher doses are associated with …

World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward

A Van Deun, T Decroo, S Tahseen, A Trébucq… - International journal of …, 2020 - Elsevier
ABSTRACT The 2018 World Health Organization (WHO) treatment guidelines for multidrug-
/rifampicin-resistant tuberculosis (MDR/RR-TB) give preference to all-oral long regimens …